Topics

FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation

17:09 EDT 12 Sep 2019 | Drugs.com

FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. today announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation...

Original Article: FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation"

Quick Search

Relevant Topic

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...